Teligene Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
61
- Latest Deal Type
-
IPO
- (Cancelled)
- Investors
-
13
Teligene General Information
Description
Developer and researcher of small-molecule drugs intended to improve cancer patient outcomes. The company is dedicated to develop innovative therapeutic approaches in oncology and small-molecule anti-tumor drugs, aiming to provide high-quality research and pharmaceutical products for healthcare practitioners to improve the lives of cancer patients.
Contact Information
Website
www.teligenebio.cnCorporate Office
- Unit 416, Building A4, Bio-Nano Park
- No. 218 Xinghu Street
- Suzhou, Jiangsu 215123
- China
Corporate Office
- Unit 416, Building A4, Bio-Nano Park
- No. 218 Xinghu Street
- Suzhou, Jiangsu 215123
- China
Teligene Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. IPO | 20-Jun-2023 | Cancelled | Clinical Trials - General | |||
| 8. Later Stage VC | 10-Feb-2021 | Completed | Clinical Trials - General | |||
| 7. Secondary Transaction - Private | 29-Jan-2021 | Completed | Clinical Trials - General | |||
| 6. Secondary Transaction - Private | 17-Sep-2020 | Completed | Clinical Trials - General | |||
| 5. Later Stage VC (Series C) | 17-Aug-2018 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC | 06-Jul-2017 | Completed | Clinical Trials - General | |||
| 3. Later Stage VC | 01-Jun-2017 | Completed | Clinical Trials - General | |||
| 2. Secondary Transaction - Private | 23-Aug-2016 | Completed | Clinical Trials - General | |||
| 1. Early Stage VC | 01-Apr-2012 | Completed | Clinical Trials - General |
Teligene Patents
Teligene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4831160-A1 | Trisubstituted quinazoline derivative, acid addition salt thereof, and pharmaceutical composition and use thereof | Pending | 05-Feb-2024 | ||
| WO-2025167927-A1 | Trisubstituted quinazoline derivative, acid addition salt thereof, and pharmaceutical composition and use thereof | Pending | 05-Feb-2024 | ||
| EP-3844166-A1 | Substituted macrocycles useful as kinase inhibitors | Active | 14-May-2019 | ||
| EP-3844166-A4 | Substituted macrocycles useful as kinase inhibitors | Active | 14-May-2019 | ||
| EP-3844166-B1 | Substituted macrocycles useful as kinase inhibitors | Active | 14-May-2019 | A61K45/06 |
Teligene Signals
Teligene Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alan Asset Management | Asset Manager | Minority | ||
| China Reform Holdings Corporation | Corporation | Minority | ||
| CICC Jia Cheng Investment Management Company | Venture Capital | Minority | ||
| Global X | VC-Backed Company | Minority | ||
| Kangcheng Capital | Growth/Expansion | Minority |
Teligene FAQs
-
When was Teligene founded?
Teligene was founded in 2011.
-
Where is Teligene headquartered?
Teligene is headquartered in Suzhou, China.
-
What is the size of Teligene?
Teligene has 61 total employees.
-
What industry is Teligene in?
Teligene’s primary industry is Pharmaceuticals.
-
Is Teligene a private or public company?
Teligene is a Private company.
-
What is Teligene’s current revenue?
The current revenue for Teligene is .
-
How much funding has Teligene raised over time?
Teligene has raised $123M.
-
Who are Teligene’s investors?
Alan Asset Management, China Reform Holdings Corporation, CICC Jia Cheng Investment Management Company, Global X, and Kangcheng Capital are 5 of 13 investors who have invested in Teligene.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process